Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical firms, like the makers of Xarelto, possess a duty to ensure that their drugs are reasonably protected for use – and failure to accomplish so may be grounds for compensation. Our lawyers are functioning hard to get these hurt by the drug the compensation they’re entitled to.
While bleeding is actually a widespread complication linked with anticoagulants, it has been alleged that Xarelto is much more harmful than classic blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This signifies that, in the occasion of an emergency, patients may be at threat for irreversible bleeding problems, such as life-threatening internal and gastrointestinal hemorrhaging.
If you or even a loved one suffered a critical bleeding event soon after taking Xarelto, you might have legal recourse. For more info, get in touch with us nowadays to have your case reviewed, totally free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future healthcare bills, lost wages, pain and suffering and, in instances of death, funeral expenditures. Furthermore, they are searching for punitive damages, that are usually awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs within the lawsuits allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in xarelto 20 mg uses users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.